REGULAR RESEARCH ARTICLE

Brain $5$-$\text{HT}_{1\text{A}}$ Receptor PET Binding, Cortisol Responses to Stress, and the Familial Transmission of Suicidal Behavior

Nadine M. Melhem, Yongqi Zhong, Jeffrey M. Miller, Francesca Zanderigo, R. Todd Ogden, M. Elizabeth Sublette, Madison Newell, Ainsley Burke, John G. Keilp, Mohammad Lesanpezeshki, Elizabeth Bartlett, David A. Brent, J. John Mann

Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States (Dr Melhem, Dr Zhong, and Dr Brent); Graduate School of Public Health, University of Pittsburgh (Dr Zhong); Molecular Imaging and Neuropathology Area, New York State Psychiatric Institute, New York, New York, United States (Dr Miller, Dr Zanderigo, Dr Ogden, Dr Sublette, Ms Newell, Dr Burke, Dr Keilp, Dr Lesanpezeshki, Dr Bartlett, and Dr Mann); Department of Psychiatry, Columbia University, New York, New York, United States (Drs Miller, Zanderigo, Sublette, Burke, Keilp, Lesanpezeshki, Bartlett, and Mann); Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, New York, United States (Dr Ogden).

Correspondence: Nadine Melhem, PhD, 3811 O'Hara Street, Pittsburgh, PA 15213, USA (melhemnm@upmc.edu).

Abstract

Background. The serotonin 1A ($5$-$\text{HT}_{1\text{A}}$) receptor has been implicated in depression and suicidal behavior. Lower resting cortisol levels are associated with higher $5$-$\text{HT}_{1\text{A}}$ receptor binding, and both differentiate suicide attempters with depression. However, it is not clear whether $5$-$\text{HT}_{1\text{A}}$ receptor binding and cortisol responses to stress are related to familial risk and resilience for suicidal behavior.

Methods. $[^1\text{C}]\text{CUMI-101}$ positron emission tomography imaging to quantify regional brain $5$-$\text{HT}_{1\text{A}}$ receptor binding was conducted in individuals considered to be at high risk for mood disorder or suicidal behavior on the basis of having a first- or second-degree relative(s) with an early onset mood disorder and history of suicidal behavior. These high-risk individuals were subdivided into the following groups: high risk resilient having no mood disorder or suicidal behavior (n = 29); high risk with mood disorder and no suicidal behavior history (n = 31); and high risk with mood disorder and suicidal behavior (n = 25). Groups were compared with healthy volunteers without a family history of mood disorder or suicidal behavior (n = 34). Participants underwent the Trier Social Stress Task (TSST). All participants were free from psychotropic medications at the time of the TSST and PET scanning.

Results. We observed no group differences in $5$-$\text{HT}_{1\text{A}}$ receptor binding considering all regions simultaneously, nor did we observe heterogeneity of the effect of group across regions. These results were similar across outcome measures ($BP_{\text{ND}}$ for all participants and $BP_p$ in a subset of the sample) and definitions of regions of interest (ROIs; standard or serotonin system-specific ROIs). We also found no group differences on TSST outcomes. Within the high risk with mood disorder and suicidal behavior group, lower $BP_p$ binding ($\beta = -0.084, SE = 0.038, P = .048$) and higher cortisol reactivity to stress ($\beta = 9.25, 95\% \text{ CI}$.}
Significance Statement

The serotonin 1A (5-HT1A) receptor and HPA axis activity are implicated in suicidal behavior. However, it is not clear whether 5-HT1A receptor binding and cortisol responses to stress are related to familial risk and resilience for suicidal behavior. Our results suggest that 5-HT1A receptor PET binding was not linked to familial risk or resilience for suicidal behavior or mood disorder. However, lower 5-HT1A receptor binding was associated with higher lethality of suicide attempt and higher cortisol reactivity to stress. Thus, altered 5-HT1A receptor binding may represent a biomarker for more severe acute suicidal ideation and higher lethality suicidal behavior. These results provide further evidence linking HPA axis dysfunction to suicidal behavior.

[3.27, 15.23], P = .004) were associated with higher lethality attempts. There were no significant relationships between 5-HT1A binding and cortisol outcomes.

Conclusions. 5-HT1A receptor binding in ROIs was not linked to familial risk or resilience protecting against suicidal behavior or mood disorder although it may be related to lethality of suicide attempt. Future studies are needed to better understand the biological mechanisms implicated in familial risk for suicidal behavior and how hypothalamic-pituitary-adrenal axis function influences such risk.

Keywords: 5-HT1A Receptor, [11C]CUMI-101 PET imaging, cortisol response to stress, familial risk, suicidal behavior

Introduction

Serotonergic system hypofunction is implicated in depression and suicidal behavior (Mann, 2013; Oquendo et al., 2014). The 5-HT1A receptor, by regulating serotonin release via the autoreceptor or by signaling on serotonin target neurons throughout the brain, is involved in mood regulation, decision-making, suicidal behavior, aggression, memory, learning, and hippocampal neurogenesis (Radley and Jacobs, 2002; Ogren et al., 2008; Wang et al., 2016). Antidepressants downregulate serotonin (5-HT)1A autoreceptors in the raphe nuclei (RN), the sole source of serotonin production and release in the brain, to augment serotonin neuron firing and release as part of their antidepressant mechanism of action (Haddjeri et al., 1998; Lan et al., 2015; Metts et al., 2019). In a meta-analysis of 10 positron emission tomography (PET) imaging studies, lower 5-HT1A receptor binding in the mesiotemporal cortex was reported in depressed patients compared with healthy controls (Wang et al., 2016). However, other studies, which were not included in this meta-analysis, found elevated binding in depression during an acute episode and between episodes in remitted patients (Miller et al., 2009; Sullivan et al., 2015; Milak et al., 2018; Pillai et al., 2018). Higher binding was also observed in offspring of parents with major depression and was highest among those who went on to develop depression, indicating that this could be a familial trait (Milak et al., 2018). We also reported that in major depressive disorder (MDD), higher autoreceptor binding in the RN predicted higher suicidal ideation up to 1 year post scan and was positively associated with 5-HT1A binding in prefrontal cortex and RN regions (Sullivan et al., 2015; Oquendo et al., 2016). It is not clear whether the discrepancy in 5-HT1A receptor binding results in depression and suicidal behavior could be due to differences in a biological phenotype related to risk and/or resilience for mood disorders or suicidal behavior.

Hypothalamic-pituitary-adrenal (HPA) axis dysregulation is associated with alterations in the serotonergic system through many mechanisms, including a decrease in hippocampal 5-HT1A receptor mediated function (Leonard, 2005; Mahar et al., 2014). Lower resting cortisol has been associated with higher 5-HT1A receptor binding in all brain regions, except in the RN (Steinberg et al., 2019). Similarly, higher 5-HT1A receptor binding in the mesiotemporal cortex was correlated with lower resting plasma cortisol (Nugent et al., 2013a). We previously reported that suicide attempters who were offspring of parents with mood disorders had lower baseline cortisol and total cortisol output during the Trier Social Stress Task (TSST) compared with offspring who never attempted suicide and with healthy controls (Melhem et al., 2015; O’Connor et al., 2017). However, to our knowledge, there are no studies comparing cortisol response to stress and 5-HT1A receptor binding in an offspring cohort of vulnerable and resilient individuals at high risk for major depression and suicidal behavior.

To address whether altered 5-HT1A receptor binding is a vulnerability or resilience biological marker for major depression and/or suicidal behavior, we conducted a PET imaging study of 5-HT1A receptor binding using [11C]CUMI-101 in medication-free high-risk individuals having a first- or second-degree relative with both an early onset mood disorder and a history of suicidal behavior. All high-risk individuals were recruited when largely beyond the age of risk for mood and suicidal behavior, allowing us to assign participants to 1 of 3 groups—vulnerable to mood disorder, vulnerable to mood disorder and suicidal behavior, or resilient because they have not developed mood disorder or made a suicide attempt (SA)—and compare them with healthy controls. We also examined the relationship of 5-HT1A receptor binding with cortisol responses to the TSST. Given our prior findings, we hypothesized higher 5-HT1A receptor binding to be a familial biological phenotype associated with risk for suicidal behavior. We also hypothesized that higher 5-HT1A receptor binding will be associated with the HPA axis biological phenotype previously associated with suicidal behavior and its familial transmission, that is, lower cortisol responses to stress.

METHODS

Sample

The sample consisted of medication-free high-risk individuals and healthy volunteers >25 years of age, an age by which mood disorder and suicidal behavior in our familial transmission studies are generally phenotypically expressed (Melhem et al., 2019). All high-risk participants had at least 1 first- or second-degree relative with early-onset mood disorder (MOOD) and a lifetime history of SA and were separated into vulnerable
and resilient groups based on their phenotype: high-risk individuals with mood disorders and a history of SA (HR-SA/MOOD, n = 25), high-risk individuals with mood disorders only (HR-MOOD, n = 31), and high-risk resilient individuals with no history of mood disorders or SA (HR-R, n = 29). Healthy volunteers (HVs, n = 34) had no personal or family history of psychiatric disorders and suicidal behavior. The sample was recruited at 2 sites, Pittsburgh and New York, in protocols approved by their respective institutional review boards, through outpatient clinics, clinician referrals, and institutional review board–approved advertisements; and these data were not previously reported on in any previous publications. Individuals with current alcohol and substance use disorders were excluded. At the New York site, individuals were included if they were unmedicated or taking medication that was ineffective after a trial of adequate dose and duration. Those individuals underwent medication taper followed by 3 weeks off medication prior to scanning. Participants across all groups were 67.2% females, mean age 38.0 years (SD = 10.1), 61.9% White, and 12.7% Hispanic. Of these participants, 86.6% completed scanning procedures, 84.9% completed the TSST, and 73.9% completed both. Participants from the 2 sites did not differ on demographic and clinical characteristics except that those from the Pittsburgh site were more likely to have comorbid anxiety disorders (42.6% vs 20.5%, \( \chi^2 = 3.63, df = 1, P = .02 \)), had higher BMI (28.7 ± 6.2 vs 24.3 ± 4.5, \( t = 4.14, P < .001 \)), and were less likely to be Hispanic (77.8% vs 95.3%, \( \chi^2 = 0.29, df = 1, P = .004 \) (supplementary Table 1). Participants at the New York site were more likely to report history of childhood abuse (24.1% vs 7.7%, \( \chi^2 = 6.17, df = 1, P = .013 \)).

Assessment

Psychiatric diagnoses were assessed in all groups, including HVs, using the Structured Clinical Interview for DSM-5 disorders (SCID-5) (First et al., 2015). Suicidal behavior was assessed using the Columbia Suicide History Form and the Columbia Suicide Severity Rating Scale (C-SSRS), which assess lifetime history of attempts, the severity of ideation, and lethality of attempts (Posner et al., 2011). Lethality was assessed using Medical Lethality Scale (Beck et al., 1975) with a score ranging between 0 and 8, where 0 corresponds to no injury and 8 to death. The scale includes anchors for the medical damage caused by the attempt dependent on the method used. Self-reported symptoms were assessed using the Beck Depression Inventory (Beck et al., 2000) and the Beck Hopelessness Inventory (Beck et al., 1974). We also assessed aggression and impulsivity using the Brown-Goodwin Lethality Scale and weighting masks were calculated as previously described (DeLorenzo et al., 2009a). PET frames were co-registered to the MRI for automated ROI labeling as previously described (DeLorenzo et al., 2009a). PET procedures to quantify 5-HT1A binding potential (BPND) and cortisol reactivity using AUC with respect to increase (AUC) following the trap-ezoid method (Pruessner et al., 2003) using raw values. We also analyzed pre-task Cort-HR. On examination of the distribution of Cort-HR, AUC_HR, and AUC_HR, we found Cort-HR and AUC_HR were not normally distributed and thus were transformed using a natural logarithmic transformation before analysis.

PET Imaging

The Pittsburgh and New York sites have standardized MRI protocols. MRI images were acquired on a GE 3 Tesla MR750 scanner at the New York site and on a Siemens 3T Trios scanner in Pittsburgh. A sagittal T1-weighted structural scan was acquired over the whole brain with the following parameters: repetition time, 6 milliseconds; echo time (TE), 2.4 milliseconds; flip angle, 8; 1-mm slice thickness (zero gap); 178 slices; and field of view, 256 × 256 mm. All images were reconstructed to a size of 256 × 256 with an isotropic resolution of 1 cubic mm. This T1-weighted structural image was used for identification of ROIs, gray-white matter segmentation, skull-stripping, and co-registration to PET images.

Image Analysis

Image analysis was performed in MATLAB (The Mathworks, Natick, MA, USA). Head motion was corrected by registering each PET frame to frame 8 using FLIRT version 5.0 (FMRI Image registration tool by the FMRI Image Analysis Group, Oxford, UK). PET-to-MRI transformations were computed, after attenuation correction, filtered back projection reconstruction, and motion corrected using FLIRT with a mutual information cost function and 6 degrees of freedom. Eight different co-registration possibilities with varying source/target images and weighting masks were calculated as previously described (DeLorenzo et al., 2009a). PET frames were co-registered to the MRI for automated ROI labeling as previously described (DeLorenzo et al., 2009b; Milak et al., 2010). After transformation, results were verified by visual inspection. Automated labels for
13 brain regions and for the reference region and cerebellar gray matter were generated from an atlas previously created and applied by our group (DeLorenzo et al., 2009b; Milak et al., 2010). ROIs consisted of anterior cingulate cortex, amygdala, cingulate cortex, dorsolateral prefrontal cortex, hippocampus, insula, medial prefrontal cortex, occipital cortex, orbitofrontal cortex, parietal cortex, parahippocampal gyrus, raphe nuclei, and temporal cortex. Probabilistic ROIs are assigned to the MRI using an automated multi-label approach (Milak et al., 2010). To calculate the probability of an ROI label for a particular voxel, the transformed template ROIs assigned to that voxel were counted and divided by the total number of templates. Cortical regions were then gray matter masked following target subject segmentation.

Primary and Secondary PET Outcome Measures

Our primary outcome measure was the binding potential \( \text{BP}_{\text{ND}} = \frac{f_{\text{ND}} \times B_{\text{avail}}}{K_d} \), where \( f_{\text{ND}} \) is the fraction of free tracer in the non-displaceable tissue compartment, \( B_{\text{avail}} \) is the concentration of 5-HT \(_1\)A receptor that is available to bind to the tracer, and \( K_d \) is the tracer equilibrium dissociation constant. \( \text{BP}_{\text{ND}} \) was used because its quantification does not require blood sampling. On an ROI level, the optimal modeling method for obtaining \( \text{BP}_{\text{ND}} \), using a reference region approach, has been determined by our group (Milak et al., 2010; Zanderigo et al., 2013) to be the simplified reference tissue model (SRTM) (Lammertsma and Hume, 1996). We therefore quantified \( \text{BP}_{\text{ND}} \) at the regional level as follows. In each participant, the tracer average time activity curve (TAC) (across all voxels) within each of the ROIs and in the gray matter cerebellum was extracted. Then, the gray matter cerebellum TAC was used in each participant as the reference tissue for the SRTM, which is implemented according to original publication in our in-house MATLAB-based software to perform kinetic modeling of PET data called BrainFit. SRTM provides an estimate of \( \text{BP}_{\text{ND}} \) in each region. SEs associated with \( \text{BP}_{\text{ND}} \) estimates were obtained according to bootstrapping procedures described elsewhere (Ogden and Tarpey, 2006; Zanderigo et al., 2013). In a subset of participants for whom 1 venous blood sample was acquired during PET imaging at 60 minutes after tracer injection, we also estimated the binding potential \( \text{BP}_p \) as previously described (Ogden, 2003; Ogden et al., 2010; Bartlett et al., 2019). Briefly, regional total distribution volume values of \( [\text{11C}]\text{CUMI-101} \) were first calculated in each participant and in each of the ROIs using Likelihood Estimation in Graphical Analysis (Ogden, 2003) and a simultaneously estimated input function with the single venous blood sample as the anchor, as previously validated (Ogden et al., 2010; Bartlett et al., 2019). Likelihood Estimation in Graphical Analysis was applied to each TACs using, at each data point in time, a weight equal to the square root of the corresponding acquisition frame duration, and a \( t^* = 45 \) minutes post injection, as previously validated (Milak et al., 2010). TACs were not corrected for vascular contribution, as multiple measures of radiotracer total radioactivity in whole blood were not available. \( \text{BP}_p \) was then calculated in each ROI as \( \text{BP}_p = V_{t_{\text{ave}}} - V_{t_{\text{ref}}} \), with \( V_{t_{\text{ave}}} \) and \( V_{t_{\text{ref}}} \) the volume of distribution estimated in the reference region, indicating the tracer’s non-displaceable binding. \( \text{BP}_p \) is an estimate of \( f_{\text{PBavail}} / K_d \), where \( f_{\text{PBavail}} \) is the number of receptors available to bind to the radiotracer, \( 1/K_d \), is the affinity of the radiotracer for the receptor, and \( f_s \) is the tracer free fraction in plasma.

For estimation of both \( \text{BP}_{\text{ND}} \) and \( \text{BP}_p \) in a new serotonin-system-specific atlas (NRU 5-HT Atlas) (Beliveau et al., 2017, 2020) (see below), voxel-level parametric maps of both binding potentials were obtained as follows. \( \text{BP}_{\text{ND}} \) was quantified at the voxel level using the reference tissue version of the likelihood estimation in graphical analysis (Zanderigo et al., 2013), which at the voxel level proved to be the method providing the closest estimation of \( \text{BP}_{\text{ND}} \) to values obtained based on arterial blood for \( [\text{11C}]\text{CUMI101} \) (Zanderigo et al., 2013). Voxel-wise \( V_s \), maps were computed for those participants with an associated single venous sample by using the input function simultaneously estimated at the ROI level (as described above) as the input to the Empirical Bayesian Estimation in Graphical Analysis (Zanderigo et al., 2010). Corresponding \( \text{BP}_p \) maps were then obtained by calculating in each voxel \( \text{BP}_p = V_s - V_{t_{\text{ref}}} \), with \( V_s \), the tracer total distribution volume estimated by Empirical Bayesian Estimation in Graphical Analysis in each voxel and \( V_{t_{\text{ref}}} \), the average \( V_s \) values among the voxels within the reference region (gray matter cerebellum).

PET Quantified in a Serotonin-Specific Atlas

In addition to quantifying \( \text{BP}_{\text{ND}} \) and \( \text{BP}_p \) in our group’s standardly considered anatomic ROIs, we also quantified \( \text{BP}_{\text{ND}} \) and \( \text{BP}_p \) in a new serotonin-specific atlas (NRU 5-HT Atlas) (Beliveau et al., 2017, 2020). This atlas was previously generated by clustering voxel-wise PET binding maps from many participants across PET tracers targeting the serotonin transporter and 1A, 1B, 2A, and 4 receptors (Beliveau et al., 2020). It includes 20 stable regions (10 in each hemisphere) that represent unique signatures of serotonin signaling across the different receptors. NRU 5-HT Atlas FreeSurfer overlays were downloaded from https://xtra.nru.dk/F5Sht-atlas/. Each participant’s T1-weighted MRI was first run through FreeSurfer 7.1.1 (http://surfer.nmr.mgh.harvard.edu/) (Fischl et al., 1999). For this analysis, gray-matter masked, voxel-wise \( \text{BP}_{\text{ND}} \) and \( \text{BP}_p \) maps quantified as described above were generated and coregistered to the MRI so that the maps could be resampled to the FreeSurfer fsaverage surface. Average \( \text{BP}_{\text{ND}} \) and \( \text{BP}_p \) estimates were then extracted from each of the 20 serotonin system-specific regions (left and right) by averaging all positive \( \text{BP}_{\text{ND}} \) or \( \text{BP}_p \) values within each region.

Statistical Analyses

We compared the 4 groups (HR-SA/MOOD, HR-MOOD, HR-R, and HV) on demographic and clinical characteristics, and on TSST measures using ANOVA with post hoc comparisons corrected for multiple comparisons. We examined group differences on TSST outcomes using linear regression with each of CORT, AUCcort, and AUC as the dependent variable and group as the independent variable and controlled for covariates significantly associated with each outcome. Group was used as a dummy variable with HV as the reference group. We also explored interactions between group and significant covariates. We used a Bonferroni correction to correct for the 3 TSST outcomes and used \( \alpha = 0.05/3 = 0.017 \) as the threshold for significance. For PET outcomes, we used a mixed-effects model approach at the ROI level with region and group as fixed effects and with participant as a random effect to analyze \( \text{BP}_{\text{ND}} \) after weighting the estimated binding values in the models according to their estimated variances (Ogden and Tarpey, 2006). We used the Lmertest package in R with the Satterthwaite’s method to compute the denominator degrees of freedom and \( F \) statistics. To prevent any individual data points from having an undue influence on the mean due
to chance underestimation of standard errors, weights were
winsorized, with the largest weights set to the weight at the
70th percentile within each region (Potter, 1990). We
controlled for sex, age, race, and site. Additional covariates were
included the model as fixed effects. We selected the most par-
simonious model as the final model, which included group as a
dummy coded variable and covariates that were significant.
To examine whether there were group differences in specific
regions of the brain, we examined group by region interaction
in these models. Before we applied mixed-effects models,
data were log transformed to stabilize the variance and be-
cause our principal hypothesis of a difference between groups
involved proportional differences across ROIs, which we and
others have previously applied (Miller et al., 2009; Sullivan
et al., 2010). Finally, we examined the rela-
tionships between BPND from various ROIs with each of CorR, AUCcor, and AUC. Exploratory analyses were also conducted on
the subset of individuals with BPND to allow comparisons to
BPcor and extant literature. Similar analyses were conducted
for standard ROIs and serotonin-specific ROIs.

RESULTS

Characteristics of the Study Sample
The HR-SA/MOOD, HR-MOOD, HR-R, and HV groups did not
differ in terms of sex, age, race, or ethnicity (Table 1). The HR-SA/
MOOD and HR-MOOD groups were more likely to have a lifetime
history of comorbid anxiety disorders compared with the HR-R
(72.7% vs 57.1% vs 14.3%, respectively, Fisher’s Exact Test [FET],
P < .001). Similar results were obtained for group differences on
current anxiety disorders. The HR-SA/MOOD group was more
likely to have a lifetime history of comorbid alcohol and sub-
stance use disorders compared with the HR-R (59.1% vs 17.9%;
FET, P = .004). The HR-SA/MOOD group was also more likely than
the HR-MOOD group to be in a current depressive episode (59.1%}

Table 1. Demographic and Clinical Characteristics, and Cortisol Outcome Measures of the Study Sample

|                  | HV  | HR-R | HR-SA/MOOD | HR-MOOD |
|------------------|-----|------|------------|---------|
| Sex, % (n) Males | 35.3 (12) | 34.5 (10) | 32.0 (8) | 29.0 (9) |
| Age, (mean ± SD) | 41.26 ± 9.83 | 36.83 ± 11.06 | 36.21 ± 10.06 | 37.03 ± 9.21 |
| Ethnicity, % (n) | 91.2 (31) | 93.1 (27) | 70.8 (17) | 90.3 (28) |
| Race, % (n) white | 61.8 (21) | 58.6 (17) | 58.3 (14) | 67.7 (21) |
| Site, % (n) NY   | 50.0 (17) | 41.4 (12) | 48.0 (12) | 41.9 (13) |
| BMI, (mean ± SD) | 25.27 ± 4.84 | 27.47 ± 5.87 | 28.56 ± 7.66 | 27.01 ± 6.68 |
| Smoking, % (n)   | 5.9 (2) | 17.2 (5) | 28.0 (7) | 29.0 (9) |
| Lifetime history of psychiatric disorders | | | | |
| Major depressive disorder, % (n) | - | - | 77.3 (17)a | 89.3 (25)b |
| Bipolar disorder, % (n) | - | - | 18.2 (4)a | 3.6 (1)b |
| Mood disorders, % (n) | - | - | 95.5 (21)a | 92.9 (26)b |
| Anxiety disorders, % (n) | - | 14.3 (4)a | 72.7 (16)a | 57.1 (16)b |
| Posttraumatic stress disorder (PTSD), % (n) | - | - | 31.8 (7)a | 7.1 (2)b |
| Alcohol and substance use disorders, % (n) | - | 17.9 (5)a | 59.1 (13)a | 28.6 (8)b |
| Current psychiatric disorders | | | | |
| Major depressive disorder, % (n) | - | - | 59.1 (13)a | 28.6 (8)b |
| Bipolar disorder, % (n) | - | - | 9.1 (2) | 0.0 (0) |
| Mood disorders, % (n) | - | - | 68.2 (15)a | 28.6 (8)b |
| Anxiety disorders, % (n) | - | 10.7 (3)a | 59.1 (13)a | 46.4 (13)b |
| Posttraumatic stress disorder (PTSD), % (n) | - | - | 9.1 (2) | 7.1 (2) |
| Alcohol and substance use disorders, % (n) | - | 0.0 (0) | 4.5 (1) | 0.0 (0) |
| Self-reported symptoms | | | | |
| Depression symptoms, (mean ± SD) | 1.53 (2.26)a | 2.03 (2.96)a | 19.20 (11.55)a | 0.35 (9.28)a |
| Hopelessness, (mean ± SD) | 1.44 ± 1.65a | 1.52 ± 2.44a | 8.84 ± 6.35a | 5.00 ± 6.24a |
| Aggression, (mean ± SD) | 12.03 (2.56)a | 13.89 (3.75)a | 20.60 (5.38)a | 16.37 (5.46)a |
| Impulsivity, (mean ± SD) | 33.83 (11.91)a | 38.04 (20.91)a | 55.70 (18.55)a | 38.96 (15.68)a |
| Family history of suicide attempt in 1st degree relatives, % (n) | - | 78.6 (22) | 71.4 (15) | 82.8 (24) |
| Psychotropic medications, % (n) | - | 6.9 (2) | 80.0 (20)a | 64.5 (20)b |
| Childhood abuse, % (n) | 2.9 (1)a | 6.9 (2)a | 40.0 (10)b | 16.1 (5)b |
| TSST measures | | | | |
| Baseline cortisol (Cort), (mean ± SD) | 0.97 ± 0.57 | 0.77 ± 0.44 | 0.88 ± 0.51 | 0.87 ± 0.55 |
| Total cortisol output (AUC), (mean ± SD) | 68.4 ± 32.9 | 55.2 ± 33.6 | 61.9 ± 37.6 | 60.5 ± 33.8 |
| Cortisol reactivity (AUC), (mean ± SD) | 10.5 ± 30.5 | 12.5 ± 34.3 | 5.54 ± 27.3 | 9.55 ± 27.5 |
| POMS before TSST (-10 mins), (mean ± SD) | 0.79 ± 14.09a | -7.43 ± 12.31a | 31.54 ± 36.96a | 11.07 ± 22.47a |
| POMS after TSST (15 mins), (mean ± SD) | 9.00 ± 19.74a | 3.86 ± 22.95a | 58.39 ± 43.18a | 20.18 ± 21.93a |
| POMS after TSST (40 mins), (mean ± SD) | 1.13 ± 13.75a | -6.54 ± 13.46a | 37.26 ± 34.00a | 10.29 ± 24.69a |

Abbreviations: HV, healthy volunteers without a family history of mood disorder or suicidal behavior; HR-R, high-risk resilient with no mood disorder or suicidal behav-
ior; HR-SA/MOOD, high-risk with mood disorder and suicidal behavior; HR-MOOD, high-risk with mood disorders and no suicidal behavior.
Superscripts are used for posthoc comparisons. POMS is the Profile of Mood States.
vs 28.6%, respectively; FET, P < .001). The HR-SA/MOOD had more severe current self-reported symptoms of depression and hopelessness, and impulsivity and aggression compared with all other groups. These clinical differences are all reported clinical correlates of suicidal behavior (Mann et al., 1999; Melhem et al., 2007; Brent et al., 2015). Finally, the HR-SA/MOOD reported higher rates of childhood physical or sexual abuse compared with all other groups.

**TSST Outcomes by Group**

Supplementary Tables 1 and 2 and supplementary Figure 1 present site differences and the relationships of all TSST outcomes with demographic and clinical characteristics, respectively. Controlling for site, and for covariates significantly associated with each of the cortisol measures (supplementary Table 2), there were no differences between the 4 groups (Table 2). Within HR-SA/MOOD, the group with a history of SA, we found higher AUCo (cortisol reactivity to stress) to be associated with maximum lethality of attempt ($\beta = 9.25$, 95% CI $[3.27, 15.23]$, $P = .004$). CORT$_{−10}$, AUCo, and AUC$_{−10}$ were not associated with self-reported severity of current depression or hopelessness and were not correlated with lifetime impulsivity and aggression across all groups. CORT$_{−10}$ was correlated with AUCo ($r = .63$, $P < .001$) and negatively correlated with AUC$_{−10}$ ($r = −.28$, $P = .005$). AUCo and AUC$_{−10}$ were also correlated ($r = 0.5$, $P < .001$).

**PET Outcomes Using Standard ROIs by Group**

Using mixed models and controlling for sex, age, race, and site, we found no overall group difference in 5-HT$_{1A}$ BP$_{ND}$ ($F[3,92.9] = 1.94$, $P = .169$). We found no significant differences between groups defined based on risk and resilience for the familial transmission of either mood disorder or suicidal behavior with regard to brain 5-HT$_{1A}$ receptor binding and cortisol responses to the TSST and no significant differences by region within the atlas ($F[19, 3938] = 1919.3$, $P = 2 \times 10^{-6}$), but no group ($F[3,99] = 1.36$, $P = .259$) or group by region interaction ($F[60, 981.4] = 1.28$, $P = .075$) effects were observed. Considering all ROIs simultaneously, BP$_{ND}$ was not associated with CORT$_{−10}$ ($\beta = .03$, $P = .316$), AUCo ($\beta = −4.1 \times 10^{-4}$, $P = .409$), or AUC$_{−10}$ ($\beta = 3.5 \times 10^{-5}$, $P = 5.8 \times 10^{-4}$).

For BP$_{p}$, there were binding differences by region within the atlas ($F[19, 912] = 514.5$, $P = 2.2 \times 10^{-10}$), but no group ($F[3,43] = 0.44$, $P = .726$) or group by region interaction ($F[60, 430.6] = 1.0$, $P = .472$) effects were observed. Considering all ROIs simultaneously, BP$_{p}$ was also not associated with CORT$_{−10}$ ($\beta = .0117$, $P = .083$, $P = .166$), AUCo ($\beta = −0.0015$, $P = .0014$, $P = .284$), or AUC$_{−10}$ ($\beta = 3.9 \times 10^{-4}$, $P = .797$).

**Discussion**

We found no significant differences between groups defined based on risk and resilience for the familial transmission of either mood disorder or suicidal behavior with regard to brain 5-HT$_{1A}$ receptor binding and cortisol responses to the TSST and no significant relationships between BP$_{p}$ and TSST outcomes of CORT$_{−10}$ ($\beta = −0.034$, $SE = 0.082$, $P = .678$), AUCo ($\beta = −0.0015$, $SE = 0.001$, $P = .26$), and AUC$_{−10}$ ($\beta = −7.7 \times 10^{-4}$, $SE = 0.0014$, $P = .593$).

### Table 2. Relationship of TSST Outcomes by Group Controlling for Covariates Significantly Associated with Each TSST Outcome

|                  | $\beta$     | 95% CI      | $P$  | Cohen’s d |
|------------------|-------------|-------------|------|-----------|
| **CORT$_{−10}$**|             |             |      |           |
| HR-SA/MOOD       | −0.12       | (−0.40, 0.16) | .403 | −0.080    |
| HR-MOOD          | −0.07       | (−0.33, 0.18) | .566 | −0.055    |
| HR-R             | 0.16        | (−0.42, 0.10) | .232 | −0.115    |
| Site, NY         | 0.19        | (−0.01, 0.38) | .065 | 0.178     |
| Ethnicity, non-Hispanic | −0.39 | (−0.71, −0.07) | .019 | −0.228    |
| **AUCo**         |             |             |      |           |
| HR-SA/MOOD       | −6.73       | (−26.0, 12.6) | .491 | −0.069    |
| HR-MOOD          | −6.06       | (−23.8, 12.4) | .502 | −0.067    |
| HR-R             | −11.8       | (−29.5, 6.4)  | .199 | −0.129    |
| Site, NY         | 16.3        | (28.4, 29.7)  | .018 | 0.239     |
| **AUC$_{−10}$**  |             |             |      |           |
| HR-SA/MOOD       | 3.55        | (−18.0, 16.0) | .658 | 0.044     |
| HR-MOOD          | −1.03       | (−13.7, 18.2) | .905 | −0.012    |
| HR-R             | 2.28        | (−12.3, 19.3) | .778 | 0.028     |
| Site, NY         | −5.54       | (−17.6, 6.55) | .365 | −0.091    |
| Race, white      | 13.8        | (14.4, 26.1)  | .029 | 0.221     |
| Smoking          | −13.3       | (−29.9, 3.31) | .115 | −0.158    |

Abbreviations: HV, healthy volunteers without a family history of mood disorder or suicidal behavior; HR-R, high-risk resilient with no mood disorder or suicidal behavior; HR-SA/MOOD, high-risk with mood disorder and suicidal behavior; HR-MOOD, high-risk with mood disorders and no suicidal behavior.
Abbreviations: HV, healthy volunteers without a family history of mood disorder or suicidal behavior; HR-R, high-risk resilient with no mood disorder or suicidal behavior; HR-SA/MOOD, high-risk with mood disorder and suicidal behavior; HR-MOOD, high-risk with mood disorders and no suicidal behavior.

Table 3. Mixed Effect Model for Weighted 5-HT₁₆ PET Binding, BPND by Group Controlling for Covariates

| Estimate | Standard Error | P     |
|----------|----------------|-------|
| Amygdala | -0.117         | 0.014 | <.001 |
| Cingulate Cortex | -0.200 | 0.012 | <.001 |
| Dorsolateral Prefrontal Cortex | -0.385 | 0.013 | <.001 |
| Hippocampus | 0.441 | 0.014 | <.001 |
| Insula | 0.170 | 0.012 | <.001 |
| Medial Prefrontal Cortex | -0.237 | 0.012 | <.001 |
| Occipital Cortex | -0.869 | 0.015 | <.001 |
| Orbitofrontal Cortex | -0.262 | 0.013 | <.001 |
| Parietal Cortex | -0.530 | 0.013 | <.001 |
| Parahippocampal Gyrus | 0.222 | 0.013 | <.001 |
| Raphe Nuclei | -0.559 | 0.014 | <.001 |
| Temporal Cortex | 0.076 | 0.012 | <.001 |
| Site, Pittsburgh | 0.018 | 0.035 | .593 |
| Sex, Males | -0.046 | 0.036 | .198 |
| Age | -0.001 | 0.002 | .760 |
| Race, White | 0.065 | 0.035 | .066 |
| HR-R | -0.043 | 0.046 | .348 |
| HR-SA/MOOD | -0.095 | 0.050 | .055 |
| HR-MOOD | -0.095 | 0.045 | .036 |

Relationship between PET binding and TSST outcomes. However, we found lower 5-HT₁₆ receptor binding, using Bₚᵣ, was associated with higher lethality attempt. We also found higher cortisol reactivity to stress to be associated with higher lethality attempt.

While we found no significant group differences on 5-HT₁₆ receptor Bₚᵣ binding in standard or serotonin-specific ROIs, we found small effect sizes in standard BPND for HR-SA/MOOD (Cohen d = −0.226) and HR-MOOD (Cohen d = −0.226) compared with HV but not for HR-R. These results suggest that 5-HT₁₆ receptor Bₚᵣ binding could be a vulnerability phenotype for the familial transmission of mood disorders and suicidal behavior. Larger studies are needed to detect such a small effect size. However, we found that when suicidal behavior occurs, lower 5-HT₁₆ receptor binding, expressed as Bₚᵣ, was significantly associated with higher lethality attempt. A prior study reported no differences in BPND binding among suicide attempters with a range of lethality compared with other high-risk and HV groups is consistent with a previous study that used Bₚᵣ as an outcome measure (Mann et al., 2019). Another study found an alternative measure of serotonin release and turnover, CSF 5-HIAA, was low only in higher lethality suicide attempters and not in lower lethality suicide attempters, indicating that abnormal serotonin function may only be detectable in those with more lethal suicidal behavior (Mann and Malone, 1997).

However, our results appear to be inconsistent with studies showing higher 5-HT₁₆ receptor binding in those with higher lethality attempts, postmortem studies showing higher binding in those who have died by suicide, and higher binding in RN predicting greater lethality of subsequent suicidal behavior (Sullivan et al., 2015; Oquendo et al., 2016; Underwood et al., 2018). Those studies used a different PET tracer and expressed binding as Bₛᵣ. We expressed our results as Bₛᵣ because arterial blood sampling was not available for all scans and with that measure could not detect a relationship with the lethality of an attempt. When we used Bₛᵣ, we found that higher lethality attempts were associated with lower binding. The difference between Bₛᵣ and Bₛᵣ is that the latter considers protein binding of the tracer in the estimation of binding, meaning more protein binding and less free fraction makes the tracer less available to entering the brain and causing an under-estimation of binding. Thus, a difference in protein binding in higher lethality suicide attempters could explain the difference in our results. Suicide attempters in our sample had a lifetime history of attempt and an early age of onset consistent with the familial nature of their phenotype (Brent et al., 2002). Moreover, they had an average lethality of attempt of 2.3, which ranges from 0 to 8, thus corresponding to physical damage requiring medical attention. These results suggest that altered 5-HT₁₆ receptor binding may represent a biomarker for more severe acute suicidal ideation (Oquendo et al., 2016) and higher lethality suicidal behavior, consistent with our earlier results (Sullivan et al., 2015; Oquendo et al., 2016).

Our results also show no significant differences in 5-HT₁₆ binding, when expressed as Bₛᵣ, in those with mood disorders with a small effect size (Cohen d = −0.204). Prior studies reported no differences in 5-HT₁₆ receptor binding in MDD (Wang et al., 2016) and a study using [11C]WAY-100635 PET scanning, expressed as Bₛᵣ, in bipolar disorders (Sargent et al., 2010). However, other studies have reported low 5-HT₁₆ Bₛᵣ in MDD (Wang et al., 2016). Patients with recurrent and familial mood disorders were previously found to have low 5-HT₁₆ receptor Bₛᵣ compared with healthy controls, in RN and mesiotemporal cortex, and to a lesser extent in other brain regions such as the occipital cortex and postcentral gyrus (Drevets et al., 1999, 2000; Savitz et al., 2009). In contrast, patients with bipolar disorders were found to have higher 5-HT₁₆ receptor binding using [18F]FCWAY Bₛᵣ, a measure of binding relative to plasma concentrations of PET tracer (Nugent et al., 2013a, 2013b). That finding in bipolar disorder is comparable with our prior work reporting higher 5-HT₁₆ receptor BP using [11C]WAY-100635 in patients with current depression or bipolar disorder (Sullivan et al., 2009; Fillai et al., 2018; Zanderigo et al., 2018), healthy high-risk offspring of parents with mood disorders (Milak et al., 2018), as well as in re-mitted MDD patients (Miller et al., 2009), suggestive of a biological trait that could confer vulnerability to depression. Some of these
discrepancies in terms of the abnormality in depression being high or low binding could be due to discrepancies in PET binding outcome measures (BP
r, BP
sat, BP
P, or BP/BP
P) and modeling approach for outcome measure estimation, the radioligand used, or the choice of a reference region (Parsey et al., 2010). Other study design factors could also play a role, including small sample sizes, medicated vs unmedicated samples, mood diagnosis, choice of control groups, and other clinical and demographic characteristics. We present our results using BP
sat, but we also reported supplementary analyses using BP, on a subgroup of our sample to allow comparisons with the extant literature.

We found no significant relationship between 5-HT
1A receptor binding expressed as BP
sat and cortisol responses to stress, but the sample size is modest. We previously reported a negative correlation between baseline salivary cortisol prior to the TSST and 5-HT
1A receptor binding, expressed as BP, in all brain regions except RN (Steinberg et al., 2019); and 5-HT
1A receptor binding, expressed as BP, in mesiotemporal cortex was also found to be negatively correlated with plasma cortisol levels (Nugent et al., 2013a). Consistent with these 2 studies, in animal studies, chronic administration of corticosteroids reduced 5-HT
1A receptor binding (McAllister-Williams et al., 2001; Man et al., 2002; Fairchild et al., 2003), and attenuation of receptor function was observed in healthy volunteers exposed to repeated cortisol administration (McAllister-Williams et al., 2007).

Although we did not find binding to correlate with cortisol responses to the TSST, we found higher cortisol reactivity to the TSST was associated with higher lethality of SA. These results are consistent with the direction of our results where lower binding was correlated with higher lethality SASs. Lower baseline or resting cortisol levels and total cortisol output throughout the TSST were also associated with higher cortisol reactivity to stress. These results are consistent with prior findings where HPA axis hyperactivity predicts risk for future suicide but is not consistently related to lower lethality suicidal behavior (Mann and Currier, 2007). We also previously reported that baseline and total cortisol output in response to stress were lower in high-risk offspring of parents with mood disorders compared with those without suicide-related behavior and healthy controls (Melhem et al., 2015). We also found this HPA axis profile to be more pronounced among suicide attempters with parental history of attempt, suggesting familial vulnerability, a finding replicated in an independent sample in the United Kingdom (O'Connor et al., 2017). We have extended these findings by showing that this biological profile precedes attempt as determined by assaying hair cortisol concentrations in patients admitted for a suicidal attempt (Melhem et al., 2017). Future studies are needed to better understand how these biological mechanisms implicated in suicidal behavior influence its familial transmission.

There are strengths and limitations of this study. This is the first study, to our knowledge, to examine 5-HT
1A receptor binding as a vulnerability and/or resilience phenotype for suicidal behavior and its familial transmission. We studied medication-free individuals to avoid effects of medication on PET results. We also examined standard ROIs and brain regional innervation patterns specific to the serotonin system and found similar results. The most important limitation is our statistical power, which is limited to detect only moderately large effect sizes in terms of Cohen d of 0.73 or larger. There were site differences in some characteristics of the study sample, and we observed higher baseline and total cortisol output in participants at the New York site. However, we controlled for site in all analyses. Lastly, while we provided 5-HT
1A quantification with 2 different binding outcome measures for comparability with the literature, we were only able to estimate BP, in a subset of participants.

In conclusion, this study did not detect a brain region with abnormal 5HT
1A receptor binding as a biomarker for familial transmission of mood disorders or suicidal behavior, although it may be related to SA lethality. We have added new evidence linking HPA axis dysfunction to suicidal behavior. Future studies are needed to better understand the biological mechanisms implicated in familial risk for suicidal behavior and how HPA axis function influences such risk.

Supplementary Materials

Supplementary data are available at International Journal of Neuropsychopharmacology (IJNPPY) online.

Acknowledgments

This study was supported by an R01 grant from the National Institute of Mental Health (MH108039, PI: Melhem; MH056390, PI: Mann). The National Institute of Mental Health did not participate in the design and conduct of the study; in the collection, management, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.

Interest Statement

Drs Melhem, Miller, Zanderigo, Ogden, Sublette, Lesanpezeshki, Bartlett, Dr Zhong, and Ms Newell have no conflict of interest to disclose. Dr Melhem’s research is currently supported by grants from the National Institute of Mental Health and the American Foundation for Suicide Prevention. Dr Burke receives royalties from the commercial use of the Columbia-Suicide Severity Rating Scale (C-SSRS). Dr Keilp and his spouse own stock in Pfizer; there are no conflicts with the work in this study. Dr Brent receives research support from NIMH, AFSP, the Once Upon a Time Foundation, and the Beckwith Foundation, receives royalties from Guilford Press, from the electronical self-rated version of the C-SSRS from eKt, Inc., and from performing duties as an UptoDate Psychiatry Section Editor, receives consulting fees from Healthwise, and receives Honoraria from the Klingenstein Third Generation Foundation for scientific board membership and grant review. Dr Mann receives royalties from the for commercial use of the C-SSRS from the Research Foundation for Mental Hygiene.

References

Barratt ES (1965) Factor analysis of some psychometric measures of impulsiveness and anxiety. Psychol Rep 16:547–554.
Bartlett EA, Ananth M, Rossano S, Zhang M, Yang J, Lin SF, Nabulsi N, Huang Y, Zanderigo F, Parsey RV, DeLorenzo C (2019) Quantification of positron emission tomography data using simultaneous estimation of the input function: validation with venous blood and replication of clinical studies. Mol Imaging Biol 21:926–934.
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J (1961) An inventory for measuring depression. Arch Gen Psychiatry 4:561–571.
Beck AT, Weissman A, Lester D, Trexler L (1974) The measurement of pessimism: the hopelessness scale. J Consult Clin Psychol 42:861–865.
Beck AT, Beck R, Kovacs M (1975) Classification of suicidal behaviors: I. Quantifying intent and medical lethality. Am J Psychiatry 132:285–287.
Kirschbaum C, Pirke KM, Hellhammer DH (1993) The ‘Trier Social Stress Test’–a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology 28:76–81.

Kumar JS, Prabhakaran J, Majo VJ, Milak MS, Hsiung SC, Tamir H, Simpson NR, Van Heertum RL, Mann JJ, Parsey RV (2007) Synthesis and in vivo evaluation of a novel 5-HT1A receptor agonist radioligand [O-methyl-11C]2-(4-(2-methoxyphenyl)piperazin-1-yl)[butyl]-4-methyl-1,2,4-triazine-3,5(2H,4H)trione in nonhuman primates. Eur J Nucl Med Mol Imaging 34:1050–1060. Lammtsera AA, Hume SF (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4:153–158.

Lan MJ, Hesselgrave N, Ciarleglio A, Ogden RT, Sullivan GM, Mann JJ, Parsey RV (2013) Higher pretreatment 5-HT1A receptor binding potential in bipolar disorder depression is associated with treatment remission: a naturalistic treatment pilot PET study. Synapse 67:773–778.

Leonard BE (2005) The HPA and immune axes in stress: the involvement of the serotonergic system. Eur Psychiatry 19 Suppl 3:S302–S306.

Mahar I, bambico FR, Mechawar N, Nobrega JN (2014) Stress, serotonin, and hippocampal neurogenesis in relation to depression and antidepressant effects. Neurosci Biobehav Rev 38:173–192.

Man MS, Young AH, McAllister-Williams RH (2002) Corticosterone modulation of somatodendritic 5-HT1A receptor function in mice. J Psychopharmacol 16:245–252.

Mann JJ (2013) The serotonergic system in mood disorders and suicidal behaviour. Philos Trans R Soc Lond B Biol Sci 368:20120537.

Mann JJ, Currier D (2007) A review of prospective studies of biologic predictors of suicidal behavior in mood disorders. Arch Suicide Res 11:3–16.

Mann JJ, Malone KM (1997) Cerebrospinal fluid amines and higher-lethality suicide attempts in depressed inpatients. Biol Psychiatry 41:162–171.

Mann JJ, Metts AV, Mathis CA, Rubin-Falcone H, Gong Z, Drevets WC, Zelazny J, Brent DA (2019) Quantification of 5-HT1A and 5-HT2A receptor binding in depressed suicide attempters and non-attempters. Arch Suicide Res 23:122–133.

Mann JJ, Waternaux C, Haas GL, Malone KM (1999) Toward a clinical model of suicidal behavior in psychiatric patients. Am J Psychiatry 156:181–189.

McAllister-Williams RH, Anderson AJ, Young AH (2001) Corticosterone selectively attenuates 8-OH-DPAT-mediated hypothermia in mice. Int J Neuropsychopharmacol 4:1–8.

McAllister-Williams RH, Massey AE, Fairchild G (2007) Repeated cortisol administration attenuates the EEG response to busiprine in healthy volunteers: evidence for desensitization of the 5-HT1A autoreceptor. J Psychopharmacol 21:826–832.

McNair D, Lorr M, Droppleman L (1992) EdITS manual for the profile of mood states. EdITS Educational and Industrial Testing Service.

Melhem NM, Brent DA, Ziegler M, Iyengar S, Kolko D, Oquendo M, Birmaher B, Burke A, Zelazny J, Stanley B, Mann JJ (2007) Familial pathways to early-onset suicidal behavior: familial and individual antecedents of suicidal behavior. Am J Psychiatry 164:1364–1370.

Melhem NM, Keilp JG, Porta G, Oquendo MA, Burke A, Stanley B, Cooper TB, Mann JJ, Brent DA (2015) Blunted HPA axis activity in suicide attempters compared to those at high risk for suicidal behavior. Neuropsychopharmacology 41:1447–1456.

Melhem NM, Munroe S, Marsland A, Gray K, Brent D, Porta G, Doualhy A, Laudenslager ML, DePietro F, Diler R, Driscoll H, Gopalan P (2017) Blunted HPA axis activity prior to suicide attempt and increased inflammation in attempters. Psychoneuroendocrinology 77:284–294.

Melhem NM, Porta G, Oquendo MA, Zelazny J, Keilp JG, Iyengar S, Burke A, Birmaher B, Stanley B, Mann JJ, Brent DA (2019) Severity...
and variability of depression symptoms predicting suicide at-
temp in high-risk individuals. JAMA Psychiatry 76:603–613.
Metts AV, Rubin-Falcone H, Ogden RT, Lin X, Wilner DE, Burke AK, Sublette ME, Oquendo MA, Miller JM, Mann JJ (2019) Anti-
depressant medication exposure and 5-HT1A autoreceptor binding in major depressive disorder. Synapse 73:e22089.
Milak MS, Severance AJ, Ogden RT, Prabhakaran J, Kumar JS, Majo VJ, Mann JJ, Parsley RV (2008) Modeling considerations for 11C-CUMI-101, an agonist radiotracer for imaging sero-
tonin 1A receptor in vivo with PET. J Nucl Med 49:587–596.
Milak MS, DeLorenzo C, Zanderigo F, Prabhakaran J, Kumar JS, Majo VJ, Mann JJ, Parsley RV (2010) In vivo quantification of human serotonin 1A receptor using 11C-CUMI-101, an agonist PET radiotracer. J Nucl Med 51:1892–1900.
Milak MS, Pantazatos S, Rashid B, Zanderigo F, DeLorenzo C, Hesselgrave N, Ogden RT, Oquendo MA, Mulhen ST, Miller JM, Burke AK, Parsley RV, Mann JJ (2018) Higher 5-HT1A autoreceptor binding as an endophenotype for major depressive disorder identified in high risk offspring - A pilot study. Psychiatry Res Neuroimaging 276:25–13.
Miller JM, Brennan KG, Ogden TR, Oquendo MA, Sullivan GM, Mann JJ, Parsley RV (2009) Elevated serotonin 1A binding in remitted major depressive disorder: evidence for a trait biological abnormality. Neuropsychopharmacology 34:2275–2284.
 Nugent AC, Bain EE, Carlson PJ, Neumeister A, Bonne O, Carson RE, Eckelmann W, Herschovit P, Zarate CA Jr, Charney DS, Drevets WC (2013a) Reduced post-synaptic sero-
tonin type 1A receptor binding in bipolar depression. Eur Neuropsychopharmacol 23:822–829.
Nugent AC, Carlson PJ, Bain EE, Eckelmann W, Herschovit P, Manji H, Zarate CA Jr, Drevets WC (2013b) Mood stabilizer treatment increases serotonin type 1A receptor binding in bi-
polar depression. J Psychopharmacol 27:894–902.
O’Connor DB, Green JA, Ferguson E, O’Carroll RE, O’Connor RC (2017) Cortisol reactivity and suicidal behavior: investigating the role of hypothalamic-pituitary-adrenal axis responses to stress in suicide attempters and ideators. Psychoneuroendocrinology 75:183–191.
Ogden RT (2003) Estimation of kinetic parameters in graphical analysis of PET imaging data. Stat Med 22:3557–3568.
Ogden RT, Tarpey T (2006) Estimation in regression models with externally estimated parameters. Biostatistics 7:115–129.
Ogden RT, Zanderigo F, Choy S, Mann JJ, Parsley RV (2010) Simul-
taneous estimation of input functions: an empirical study. J Cereb Blood Flow Metab 30:816–826.
Ogren SO, Eriksson TM, Elvander-Tottie E, D’Addario C, Ekström JC, Svenningsson P, Meister B, Kehr J, Stiedl O (2008) The role of 5-HT(1A) receptors in learning and memory. Behav Brain Res 195:54–77.
Oquendo MA, Sullivan GM, Sudol K, Baca-Garcia E, Stanley BH, Sublette ME, Mann JJ (2014) Toward a biosignature for suicide. Am J Psychiatry 171:1259–1277.
Oquendo MA, Galfalvy H, Sullivan GM, Miller JM, Milak MM, Sublette ME, Cisneros-Trujillo S, Burke AK, Parsley RV, Mann JJ (2016) Positron emission tomographic imaging of the serotonergic system and prediction of risk and lethality of future suicidal behavior. JAMA Psychiatry 73:1048–1055.
Parsley RV, Slifstein M, Hwang DR, Abi-Dargham A, Simpson N, Mawlawi O, Guo NN, Van Heertum R, Mann JJ, Laruelle M (2000) Validation and reproducibility of measurement of 5-HT1A receptor parameters with [carbonyl-(11)C]WAY-100635 in humans: comparison of arterial and reference tissue input functions. J Cereb Blood Flow Metab 20:1111–1133.
Parsley RV, Ogden RT, Miller JM, Tin A, Hesselgrave N, Goldstein E, Mikhno A, Milak M, Zanderigo F, Sullivan GM, Oquendo MA, Mann JJ (2010) Higher serotonin 1A binding in a second major depression cohort: modeling and reference region consider-
ations. Biol Psychiatry 68:170–178.
Pillai RL, Zhang M, Yang J, Boldrini M, Mann JJ, Oquendo MA, Parsley RV, DeLorenzo C (2018) Will imaging individual raphé nuclei in males with major depressive disorder enhance diagnostic sensitivity and specificity? Depress Anxiety 35:411–420.
Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ (2011) The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. AJP 168:1266–1277.
Potter F (1990) A study of procedures to identify and trim extre-
me sampling weights. In: Proceedings of the section on survey research methods. JSM proceedings of the Section, American Statistical Association, AMSTAT, 225–230.
Pruessner JC, Kirschbaum C, Meinlschmid G, Hellhammer DH (2003) Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change. Psychoneuroendocrinology 28:916–931.
Radley JJ, Jacobs BL (2002) 5-HT1A receptor antagonist adminis-
tration decreases cell proliferation in the dentate gyrus. Brain Res 955:264–267.
Sargent PA, Rabiner EA, Bhagwagar Z, Clark L, Cowen P, Goodwin GM, Grasby PM (2010) 5-HT(1A) receptor binding in euthymic bipolar patients using positron emission tomography with [carbonyl-(11)C]WAY-100635. J Affect Disord 123:77–80.
Savitz J, Lucki I, Drevets WC (2009) 5-HT(1A) receptor function in major depressive disorder. Prog Neurobiol 88:17–31.
Steinberg LJ, Rubin-Falcone H, Galfalvy HC, Kaufman J, Miller JM, Sublette ME, Cooper TB, Min E, Keilp JG, Stanley BH, Oquendo MA, Ogden RT, Mann JJ (2019) Cortisol stress re-
sponse and in vivo PET imaging of human brain serotonin 1A receptor binding. Int J Neuropsychopharmacol 22:329–338.
Sullivan GM, Ogden RT, Oquendo MA, Kumar JS, Simpson N, Huang YY, Mann JJ, Parsley RV (2009) Positron emission tomography quantification of serotonin-1A receptor binding in medication-free bipolar depression. Biol Psychiatry 66:223–230.
Sullivan GM, Oquendo MA, Milak M, Miller JM, Burke A, Ogden RT, Parsley RV, Mann JJ (2015) Positron emission tomography quantification of serotonin(1A) receptor binding in suicide attempters with major depressive disorder. JAMA Psychiatry 72:169–178.
Underwood MD, Kassir SA, Bakalian MJ, Galfalvy H, Dwork AJ, Mann JJ, Arango V (2018) Serotonin receptors and suicide, major depression, alcohol use disorder and reported early life adversity. Transl Psychiatry 8:279.
Wang L, Zhou C, Zhu D, Wang X, Fang L, Zhong J, Mao Q, Sun L, Gong X, Xia J, Lian B, Xie P (2016) Serotonin-1A receptor alter-
tations in depression: a meta-analysis of molecular imaging studies. BMC Psychiatry 16:319.
Zanderigo F, Ogden RT, Bertoldo A, Cobelli C, Mann JJ, Parsley RV (2010) Empirical Bayesian estimation in graphical analysis: a voxel-based approach for the determination of the volume of distribution in PET studies. Nucl Med Biol 37:443–451.
Zanderigo F, Ogden RT, Parsley RV (2013) Reference region ap-
proaches in PET: a comparative study on multiple radioligands. J Cereb Blood Flow Metab 33:888–897.
Zanderigo F, Pantazatos S, Rubin-Falcone H, Ogden RT, Chhetry BT, Sullivan G, Oquendo M, Miller JM, Mann JJ (2018) In vivo relationship between serotonin 1A receptor binding and gray matter volume in the healthy brain and in major depressive disorder. Brain Struct Funct 223:2609–2625.